Economic Analysis of an Optical Neonatal Skin Maturity Meter (MOMPN) in Brazilian Newborns
Author(s)
Lilian Reinaldi R Pirozi, Dr, Dr1, Myrianne Barbosa, Dr2, Thiago Godoy, Dr, Dr1, Rodney Guimarães, Dr, Dr3, Marcelo Eidi Nita, Dr, MSc, PhD, MD1.
1MapeSolutions, São Paulo, Brazil, 2HTA/HEOR, MapeSolutions, São Paulo, Brazil, 3BirthTech, Belo Horizonte, Brazil.
1MapeSolutions, São Paulo, Brazil, 2HTA/HEOR, MapeSolutions, São Paulo, Brazil, 3BirthTech, Belo Horizonte, Brazil.
OBJECTIVES: To conduct a cost-effectiveness and budget impact analysis of the MOMPN for newborns with suspected prematurity compared to conventional methods: unreliable last mestrual period (DUM), reliable last menstrual period (DUMC), and ultrasonography (USG) in newborns.
METHODS: A decision tree model was constructed with a one-year time horizon, a 5% annual discount rate, and the public player perspective. Diagnostic accurary data for determining gestational age and identifying premature newborns were obtained form the published literature. The incremental cost-effectiveness threshold estimated for Brazil.The budget impact analysis considered a market share ranging form 5% to 30% over fiver years.Model robustness was explored through sensitivity analyses. The study followed CHEERS guidelines
RESULTS: The incremental cost of MOMPN was R$ -3,723.15 compared to DUMN, R$ - 1,220.40 compared to DUMC, and R$ 864.08 compared to USG. The greatest effectiveness gain was observed in the comparasion with DUMN, where the difference was 0.20. The ICER was R$ 18,764.44, well below the established threshold,In the proposed scenario, the adoption of MOMPN would result in cost savings of R$ 56,075,733.00 in the first year. The budget impact analysis projected cumulative savings of R$ 1 billion over fuve years compared to the current standard of care
CONCLUSIONS: MOMPN is cost-effective and has the potential to generate up to R$1 billion and 50 million in savings if incorpotrated into the health system. The efficiency of the MONPN, combined with is ease of use and the ability to reuse the same device across multiple patients, makes it a valuable tool for managing the health of newborns with suspected prematurity
METHODS: A decision tree model was constructed with a one-year time horizon, a 5% annual discount rate, and the public player perspective. Diagnostic accurary data for determining gestational age and identifying premature newborns were obtained form the published literature. The incremental cost-effectiveness threshold estimated for Brazil.The budget impact analysis considered a market share ranging form 5% to 30% over fiver years.Model robustness was explored through sensitivity analyses. The study followed CHEERS guidelines
RESULTS: The incremental cost of MOMPN was R$ -3,723.15 compared to DUMN, R$ - 1,220.40 compared to DUMC, and R$ 864.08 compared to USG. The greatest effectiveness gain was observed in the comparasion with DUMN, where the difference was 0.20. The ICER was R$ 18,764.44, well below the established threshold,In the proposed scenario, the adoption of MOMPN would result in cost savings of R$ 56,075,733.00 in the first year. The budget impact analysis projected cumulative savings of R$ 1 billion over fuve years compared to the current standard of care
CONCLUSIONS: MOMPN is cost-effective and has the potential to generate up to R$1 billion and 50 million in savings if incorpotrated into the health system. The efficiency of the MONPN, combined with is ease of use and the ability to reuse the same device across multiple patients, makes it a valuable tool for managing the health of newborns with suspected prematurity
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HTA35
Topic
Health Technology Assessment
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Pediatrics